查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1554400

2024-2032 年日本细胞和基因治疗市场报告（按治疗类型、适应症、交付模式、最终用户和地区划分）

Japan Cell and Gene Therapy Market Report by Therapy Type, Indication, Delivery Mode, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 121 Pages | 商品交期: 5-7个工作天内

价格
简介目录

日本细胞和基因治疗市场规模预计在 2024 年至 2032 年期间将呈现 38.87% 的成长率 (CAGR)。慢性病和遗传疾病的日益普及正在推动对能够解决这些医疗保健挑战的先进疗法的需求，这主要推动了市场的成长。

细胞和基因疗法是尖端的医学方法，为治疗各种疾病和病症带来了巨大的希望。从本质上讲，细胞疗法涉及移植或操纵活细胞来替换或修復体内受损或故障的组织。这可以包括使用干细胞来再生受损的器官或组织。另一方面，基因治疗则着重于修改或纠正导致疾病的错误基因。这可以透过在患者细胞内引入、替换或修復特定基因来实现。细胞和基因疗法都处于个人化医疗的前沿，提供了提供有针对性的个人化治疗的潜力，可以解决疾病的根本原因，而不仅仅是控制症状。这些创新疗法在临床试验中取得了显着的成功，并为医疗保健的新时代铺平了道路，有可能彻底改变遗传性疾病、癌症和其他一系列具有挑战性的医疗状况的治疗。

日本细胞和基因治疗市场趋势：

日本细胞和基因疗法市场正在迅速崛起，成为该国医疗保健领域一个充满活力且前景光明的领域。随着人口老化和慢性病负担的日益加重，对能够提供长期解决方案的创新疗法的需求不断增加。细胞和基因疗法因其解决未满足的医疗需求的潜力而在日本获得了极大的关注和投资。日本研究人员和生物製药公司一直积极致力于利用这些尖端技术开发新疗法。日本监管机构也采取措施促进细胞和基因疗法的临床开发和商业化，使其成为对国内和国际参与者有吸引力的市场。学术界、工业界和医疗保健提供者之间的合作以及精准医疗方法的日益采用进一步推动了市场的成长。因此，日本细胞和基因治疗市场有望持续扩张，并可能在该国未来的医疗保健中发挥关键作用。

日本细胞和基因治疗市场细分：

IMARC Group提供了每个细分市场的主要趋势的分析，以及 2024-2032 年国家层级的预测。我们的报告根据治疗类型、适应症、给药模式和最终用户对市场进行了分类。

治疗类型见解：

  • 细胞疗法
    • 干细胞
    • 非干细胞
  • 基因治疗

该报告根据治疗类型对市场进行了详细的细分和分析。这包括细胞疗法（干细胞和非干细胞）和基因疗法。

指示见解：

  • 心血管疾病
  • 肿瘤疾病
  • 遗传性疾病
  • 传染病
  • 神经系统疾病
  • 其他的

报告还提供了基于指示的详细市场细分和分析。这包括心血管疾病、肿瘤疾病、遗传疾病、传染病、神经系统疾病等。

交付模式见解：

  • 体内
  • 离体

该报告根据交付模式对市场进行了详细的细分和分析。这包括体内和离体。

最终使用者见解：

  • 医院
  • 癌症护理中心
  • 製药和生物技术公司
  • 其他的

报告还提供了基于最终用户的详细市场细分和分析。这包括医院、癌症护理中心、製药和生物技术公司等。

区域见解：

  • 关东地区
  • 关西/近畿地区
  • 中部/中部地区
  • 九州·冲绳地区
  • 东北部地区
  • 中国地区
  • 北海道地区
  • 四国地区

该报告还对所有主要区域市场进行了全面分析，包括关东地区、关西/近畿地区、中部/中部地区、九州冲绳地区、东北地区、中国地区、北海道地区和四国地区。

竞争格局：

市场研究报告也对竞争格局进行了全面分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外，也提供了所有主要公司的详细资料。

本报告回答的关键问题：

  • 日本细胞和基因治疗市场到目前为止表现如何，未来几年又会如何表现？
  • COVID-19 对日本细胞和基因治疗市场有何影响？
  • 日本细胞和基因治疗市场按治疗类型划分是怎样的？
  • 根据适应症，日本细胞和基因治疗市场的细分情况如何？
  • 日本细胞和基因疗法市场在交付模式上的划分是怎么样的？
  • 日本细胞和基因治疗市场的最终用户细分情况如何？
  • 日本细胞和基因治疗市场价值链的各个阶段是什么？
  • 日本细胞和基因治疗的关键驱动因素和挑战是什么？
  • 日本细胞和基因治疗市场的结构如何？
  • 日本细胞和基因治疗市场的竞争程度如何？

本报告回答的关键问题：

  • 日本细胞和基因治疗市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对日本细胞和基因治疗市场有何影响？
  • 日本细胞和基因治疗市场按治疗类型划分是怎样的？
  • 根据适应症，日本细胞和基因治疗市场的细分情况如何？
  • 日本细胞和基因疗法市场在交付模式方面的细分情况如何？
  • 日本细胞和基因治疗市场的最终用户细分情况如何？
  • 日本细胞和基因治疗市场价值链的各个阶段是什么？
  • 日本细胞和基因治疗的关键驱动因素和挑战是什么？
  • 日本细胞和基因治疗市场的结构如何？
  • 日本细胞和基因治疗市场的竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：日本细胞与基因治疗市场 - 简介

  • 概述
  • 市场动态
  • 产业动态
  • 竞争情报

第 5 章：日本细胞与基因疗法市场格局

  • 历史与当前市场趋势（2018-2023）
  • 市场预测（2024-2032）

第 6 章：日本细胞和基因治疗市场 - 细分：按治疗类型

  • 细胞疗法
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔
      • 干细胞
      • 非干细胞
    • 市场预测（2024-2032）
  • 基因治疗
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 7 章：日本细胞和基因治疗市场 - 细分：按迹象分类

  • 心血管疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 肿瘤疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 遗传性疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 传染病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 神经系统疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 其他的
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 8 章：日本细胞和基因治疗市场 - 细分：按交付模式

  • 体内
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 离体
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 9 章：日本细胞和基因治疗市场 - 细分：按最终用户划分

  • 医院
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 癌症护理中心
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 製药和生物技术公司
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 其他的
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 10 章：日本细胞和基因治疗市场 - 细分：按地区

  • 关东地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：按治疗类型
    • 市场区隔：依指标
    • 市场区隔：以交付方式
    • 市场区隔：按最终用户
    • 关键参与者
    • 市场预测（2024-2032）
  • 关西/近畿地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：按治疗类型
    • 市场区隔：依指标
    • 市场区隔：以交付方式
    • 市场区隔：按最终用户
    • 关键参与者
    • 市场预测（2024-2032）
  • 中部/中部地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：按治疗类型
    • 市场区隔：依指标
    • 市场区隔：以交付方式
    • 市场区隔：按最终用户
    • 关键参与者
    • 市场预测（2024-2032）
  • 九州·冲绳地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：按治疗类型
    • 市场区隔：依指标
    • 市场区隔：以交付方式
    • 市场区隔：按最终用户
    • 关键参与者
    • 市场预测（2024-2032）
  • 东北部地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：按治疗类型
    • 市场区隔：依指标
    • 市场区隔：以交付方式
    • 市场区隔：按最终用户
    • 关键参与者
    • 市场预测（2024-2032）
  • 中国地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：按治疗类型
    • 市场区隔：依指标
    • 市场区隔：以交付方式
    • 市场区隔：按最终用户
    • 关键参与者
    • 市场预测（2024-2032）
  • 北海道地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：按治疗类型
    • 市场区隔：依指标
    • 市场区隔：以交付方式
    • 市场区隔：按最终用户
    • 关键参与者
    • 市场预测（2024-2032）
  • 四国地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：按治疗类型
    • 市场区隔：依指标
    • 市场区隔：以交付方式
    • 市场区隔：按最终用户
    • 关键参与者
    • 市场预测（2024-2032）

第 11 章：日本细胞与基因疗法市场 - 竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳制胜策略
  • 竞争仪表板
  • 公司评估象限

第 12 章：关键参与者简介

  • Company A
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

此处未提供公司名称，因为这是目录范例。最终报告中提供完整的清单。

第 13 章：日本细胞与基因治疗市场 - 产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 司机
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 14 章：附录

简介目录
Product Code: SR112024A17931

Japan cell and gene therapy market size is projected to exhibit a growth rate (CAGR) of 38.87% during 2024-2032. The increasing adoption of chronic and genetic diseases is propelling the demand for advanced therapies capable of addressing these healthcare challenges, which is primarily driving the market growth.

Cell and gene therapy are cutting-edge medical approaches that hold immense promise for the treatment of various diseases and conditions. In essence, cell therapy involves the transplantation or manipulation of living cells to replace or repair damaged or malfunctioning tissues within the body. This can include the use of stem cells to regenerate damaged organs or tissues. On the other hand, gene therapy focuses on modifying or correcting faulty genes responsible for causing diseases. This can be achieved by introducing, replacing, or repairing specific genes within a patient's cells. Both cell and gene therapy are at the forefront of personalized medicine, offering the potential to provide targeted, individualized treatments that can address the root causes of diseases, rather than just managing their symptoms. These innovative therapies have shown remarkable success in clinical trials and are paving the way for a new era in healthcare, with the potential to revolutionize the treatment of genetic disorders, cancer, and a range of other challenging medical conditions.

Japan Cell and Gene Therapy Market Trends:

The Japan cell and gene therapy market is rapidly emerging as a dynamic and promising sector within the country's healthcare landscape. With an aging population and a growing burden of chronic diseases, there is a heightened demand for innovative treatments that can offer long-term solutions. Cell and gene therapy have gained significant attention and investment in Japan due to their potential to address unmet medical needs. Japanese researchers and biopharmaceutical companies have been actively engaged in developing novel therapies using these cutting-edge technologies. Regulatory authorities in Japan have also taken steps to facilitate the clinical development and commercialization of cell and gene therapies, making it an attractive market for both domestic and international players. The market's growth is further fueled by collaborations between academia, industry, and healthcare providers, as well as the increasing adoption of precision medicine approaches. As a result, the Japan cell and gene therapy market is poised for continued expansion and is likely to play a pivotal role in the future of healthcare in the country.

Japan Cell and Gene Therapy Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on therapy type, indication, delivery mode, and end user.

Therapy Type Insights:

  • Cell Therapy
    • Stem Cell
    • Non-Stem Cell
  • Gene Therapy

The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes cell therapy (stem cell and non-stem cell) and gene therapy.

Indication Insights:

  • Cardiovascular Disease
  • Oncology Disorder
  • Genetic Disorder
  • Infectious Disease
  • Neurological Disorder
  • Others

A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes cardiovascular disease, oncology disorder, genetic disorder, infectious disease, neurological disorder, and others.

Delivery Mode Insights:

  • In-Vivo
  • Ex-Vivo

The report has provided a detailed breakup and analysis of the market based on the delivery mode. This includes in-vivo and ex-vivo.

End User Insights:

  • Hospitals
  • Cancer Care Centers
  • Pharmaceutical and Biotechnology Companies
  • Others

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, cancer care centers, pharmaceutical and biotechnology companies, and others.

Regional Insights:

  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region

The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan cell and gene therapy market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan cell and gene therapy market?
  • What is the breakup of the Japan cell and gene therapy market on the basis of therapy type?
  • What is the breakup of the Japan cell and gene therapy market on the basis of indication?
  • What is the breakup of the Japan cell and gene therapy market on the basis of delivery mode?
  • What is the breakup of the Japan cell and gene therapy market on the basis of end user?
  • What are the various stages in the value chain of the Japan cell and gene therapy market?
  • What are the key driving factors and challenges in the Japan cell and gene therapy?
  • What is the structure of the Japan cell and gene therapy market and who are the key players?
  • What is the degree of competition in the Japan cell and gene therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cell and Gene Therapy Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Cell and Gene Therapy Market Landscape

  • 5.1 Historical and Current Market Trends (2018-2023)
  • 5.2 Market Forecast (2024-2032)

6 Japan Cell and Gene Therapy Market - Breakup by Therapy Type

  • 6.1 Cell Therapy
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2018-2023)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Stem Cell
      • 6.1.3.2 Non-Stem Cell
    • 6.1.4 Market Forecast (2024-2032)
  • 6.2 Gene Therapy
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2018-2023)
    • 6.2.3 Market Forecast (2024-2032)

7 Japan Cell and Gene Therapy Market - Breakup by Indication

  • 7.1 Cardiovascular Disease
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2018-2023)
    • 7.1.3 Market Forecast (2024-2032)
  • 7.2 Oncology Disorder
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2018-2023)
    • 7.2.3 Market Forecast (2024-2032)
  • 7.3 Genetic Disorder
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2018-2023)
    • 7.3.3 Market Forecast (2024-2032)
  • 7.4 Infectious Disease
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2018-2023)
    • 7.4.3 Market Forecast (2024-2032)
  • 7.5 Neurological Disorder
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2018-2023)
    • 7.5.3 Market Forecast (2024-2032)
  • 7.6 Others
    • 7.6.1 Historical and Current Market Trends (2018-2023)
    • 7.6.2 Market Forecast (2024-2032)

8 Japan Cell and Gene Therapy Market - Breakup by Delivery Mode

  • 8.1 In-Vivo
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2018-2023)
    • 8.1.3 Market Forecast (2024-2032)
  • 8.2 Ex-Vivo
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2018-2023)
    • 8.2.3 Market Forecast (2024-2032)

9 Japan Cell and Gene Therapy Market - Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2018-2023)
    • 9.1.3 Market Forecast (2024-2032)
  • 9.2 Cancer Care Centers
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2018-2023)
    • 9.2.3 Market Forecast (2024-2032)
  • 9.3 Pharmaceutical and Biotechnology Companies
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2018-2023)
    • 9.3.3 Market Forecast (2024-2032)
  • 9.4 Others
    • 9.4.1 Historical and Current Market Trends (2018-2023)
    • 9.4.2 Market Forecast (2024-2032)

10 Japan Cell and Gene Therapy Market - Breakup by Region

  • 10.1 Kanto Region
    • 10.1.1 Overview
    • 10.1.2 Historical and Current Market Trends (2018-2023)
    • 10.1.3 Market Breakup by Therapy Type
    • 10.1.4 Market Breakup by Indication
    • 10.1.5 Market Breakup by Delivery Mode
    • 10.1.6 Market Breakup by End User
    • 10.1.7 Key Players
    • 10.1.8 Market Forecast (2024-2032)
  • 10.2 Kansai/Kinki Region
    • 10.2.1 Overview
    • 10.2.2 Historical and Current Market Trends (2018-2023)
    • 10.2.3 Market Breakup by Therapy Type
    • 10.2.4 Market Breakup by Indication
    • 10.2.5 Market Breakup by Delivery Mode
    • 10.2.6 Market Breakup by End User
    • 10.2.7 Key Players
    • 10.2.8 Market Forecast (2024-2032)
  • 10.3 Central/ Chubu Region
    • 10.3.1 Overview
    • 10.3.2 Historical and Current Market Trends (2018-2023)
    • 10.3.3 Market Breakup by Therapy Type
    • 10.3.4 Market Breakup by Indication
    • 10.3.5 Market Breakup by Delivery Mode
    • 10.3.6 Market Breakup by End User
    • 10.3.7 Key Players
    • 10.3.8 Market Forecast (2024-2032)
  • 10.4 Kyushu-Okinawa Region
    • 10.4.1 Overview
    • 10.4.2 Historical and Current Market Trends (2018-2023)
    • 10.4.3 Market Breakup by Therapy Type
    • 10.4.4 Market Breakup by Indication
    • 10.4.5 Market Breakup by Delivery Mode
    • 10.4.6 Market Breakup by End User
    • 10.4.7 Key Players
    • 10.4.8 Market Forecast (2024-2032)
  • 10.5 Tohoku Region
    • 10.5.1 Overview
    • 10.5.2 Historical and Current Market Trends (2018-2023)
    • 10.5.3 Market Breakup by Therapy Type
    • 10.5.4 Market Breakup by Indication
    • 10.5.5 Market Breakup by Delivery Mode
    • 10.5.6 Market Breakup by End User
    • 10.5.7 Key Players
    • 10.5.8 Market Forecast (2024-2032)
  • 10.6 Chugoku Region
    • 10.6.1 Overview
    • 10.6.2 Historical and Current Market Trends (2018-2023)
    • 10.6.3 Market Breakup by Therapy Type
    • 10.6.4 Market Breakup by Indication
    • 10.6.5 Market Breakup by Delivery Mode
    • 10.6.6 Market Breakup by End User
    • 10.6.7 Key Players
    • 10.6.8 Market Forecast (2024-2032)
  • 10.7 Hokkaido Region
    • 10.7.1 Overview
    • 10.7.2 Historical and Current Market Trends (2018-2023)
    • 10.7.3 Market Breakup by Therapy Type
    • 10.7.4 Market Breakup by Indication
    • 10.7.5 Market Breakup by Delivery Mode
    • 10.7.6 Market Breakup by End User
    • 10.7.7 Key Players
    • 10.7.8 Market Forecast (2024-2032)
  • 10.8 Shikoku Region
    • 10.8.1 Overview
    • 10.8.2 Historical and Current Market Trends (2018-2023)
    • 10.8.3 Market Breakup by Therapy Type
    • 10.8.4 Market Breakup by Indication
    • 10.8.5 Market Breakup by Delivery Mode
    • 10.8.6 Market Breakup by End User
    • 10.8.7 Key Players
    • 10.8.8 Market Forecast (2024-2032)

11 Japan Cell and Gene Therapy Market - Competitive Landscape

  • 11.1 Overview
  • 11.2 Market Structure
  • 11.3 Market Player Positioning
  • 11.4 Top Winning Strategies
  • 11.5 Competitive Dashboard
  • 11.6 Company Evaluation Quadrant

12 Profiles of Key Players

  • 12.1 Company A
    • 12.1.1 Business Overview
    • 12.1.2 Services Offered
    • 12.1.3 Business Strategies
    • 12.1.4 SWOT Analysis
    • 12.1.5 Major News and Events
  • 12.2 Company B
    • 12.2.1 Business Overview
    • 12.2.2 Services Offered
    • 12.2.3 Business Strategies
    • 12.2.4 SWOT Analysis
    • 12.2.5 Major News and Events
  • 12.3 Company C
    • 12.3.1 Business Overview
    • 12.3.2 Services Offered
    • 12.3.3 Business Strategies
    • 12.3.4 SWOT Analysis
    • 12.3.5 Major News and Events
  • 12.4 Company D
    • 12.4.1 Business Overview
    • 12.4.2 Services Offered
    • 12.4.3 Business Strategies
    • 12.4.4 SWOT Analysis
    • 12.4.5 Major News and Events
  • 12.5 Company E
    • 12.5.1 Business Overview
    • 12.5.2 Services Offered
    • 12.5.3 Business Strategies
    • 12.5.4 SWOT Analysis
    • 12.5.5 Major News and Events

Company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

13 Japan Cell and Gene Therapy Market - Industry Analysis

  • 13.1 Drivers, Restraints, and Opportunities
    • 13.1.1 Overview
    • 13.1.2 Drivers
    • 13.1.3 Restraints
    • 13.1.4 Opportunities
  • 13.2 Porters Five Forces Analysis
    • 13.2.1 Overview
    • 13.2.2 Bargaining Power of Buyers
    • 13.2.3 Bargaining Power of Suppliers
    • 13.2.4 Degree of Competition
    • 13.2.5 Threat of New Entrants
    • 13.2.6 Threat of Substitutes
  • 13.3 Value Chain Analysis

14 Appendix